Thiazide diuretics cut risk of fractures in Alzheimer's patients

23 April 2019
alzheimer-s-big

The use of thiazide diuretics was associated with a decreased risk of low energy fractures in people with Alzheimer’s disease, a new study from the University of Eastern Finland shows.

The association was found in long-term use exceeding three years; however, shorter term use did not reduce the risk of fractures. Thiazides are typically prescribed to treat hypertension. The results were published in Osteoporosis International.

Hip fracture was the most common low energy fracture in the study population, and the risk of this fracture type decreased by 30% in long-term thiazide use. The association may be related to the fact that thiazides decrease urinary calcium excretion and increase bone mineral density, which may decrease the risk of fracture in case of a fall. Persons with Alzheimer’s disease have an increased risk of falling, as the disease leads to problems in balance and spatial orientation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical